Clinical remission in best performers severe asthmatic patients treated for three years with mepolizumab.

<bold>Background:</bold> In its severe form, where possible asthma is treated biological drugs, in order to reduce as much as possible, the use of systemic steroid. Mepolizumab is effective for severe asthma based on key outcomes such as exacerbations and steroid dependence. Its efficacy in terms of criteria for clinical remission in the short and long term has become of interest. <bold>Objective:</bold> To evaluate the effect of mepolizumab in the achievement of clinical remission after 3 years of administration. <bold>Methods:</bold> In this study, 71 patients who continued mepolizumab for 3 years were assessed for clinical remission according to six different published sets of remission criteria. <bold>Results:</bold> According to the criteria, 39%-52% of patients experienced complete remission in the first year, increasing to 51%–73% at 3 years. Classifying patients according to partial and complete remission criteria, proposed by SANI, we observe that 22% of patients in partial remission at first year, achieving a complete remission at third. Baseline factors associated with earlier remission were higher FEV1 if we consider classifications requiring FEV1 ≥ 80%, low OCS dose and FeNO levels in the one requiring FEV1 stabilization. <bold>Conclusion:</bold> Clinical remission is possible for patients treated with mepolizumab. Observations at 3 years compared with the first year indicated that factors negatively affecting remission delayed rather than prevented it. Earlier treatment could increase the chances of remission.